By Steven Reinberg, HealthDay Reporter

TUESDAY, Jan. 8, 2019 (HealthDay News) -- Over the past 25 years, the number of Americans who have died from cancer has dropped dramatically, though racial and economic disparities persist, a new study reveals.

Between 1991 and 2016, deaths from cancer dropped 27 percent. In real numbers, that's almost 2.6 million fewer cancer deaths, according to the American Cancer Society.

This is especially true for the most common cancers, including breast, colon, lung and prostate.

But although the racial gap in cancer deaths is slowly narrowing, socioeconomic disparities are growing, she said. Poor counties in particular lag behind, and for some cancers the gap is widening, Siegel noted.

"The largest gaps are for the most preventable cancers," she said. For example, in the early 1970s, colon cancer death rates were 20 percent lower in poor counties, and today they are 35 percent higher, when compared with people living in richer counties, Siegel said.

"Differences in wealth lead to differences in risk factors and less access to high-quality care for prevention, early detection and treatment," she explained.

In addition, poor people are less likely to be screened for cancer, and so cancer is likely to be diagnosed at an advanced stage that makes treatment problematic. Plus, care for the poor is not as good as that given to the rich, Siegel said.

Where the poor have access to screening, these disparities can be eliminated, she suggested. "We have seen this in Massachusetts and Washington, D.C.," she said.

In addition, more education is called for to help people understand the steps they can take to lower their risk for cancer. "Health literacy is an issue," Siegel said.

The report was published online Jan. 8 in CA: A Cancer Journal for Clinicians.

According to Electra Paskett, co-program leader of the cancer control program at Ohio State University's Comprehensive Cancer Center, "The people who suffer the most are impacted by social determinants of health, which include where they live, their socioeconomic condition, their education, their income."

Poor people face so many problems just living day-to-day. And when they are confronted by cancer, they often don't have the access to the latest treatments, Paskett explained.

The new report noted that nearly 2 million Americans will be diagnosed with cancer this year, and more than 600,000 will die of the disease. But the cancer death rate has actually been dropping nearly 2 percent a year, from 215 deaths per 100,000 in 1991 to 156 per 100,000 in 2016.

Between 1990 and 2016, deaths from lung cancer among men dropped 48 percent, and deaths from breast cancer among women decreased 40 percent. From 1993 to 2016, deaths from prostate cancer dropped 51 percent, and from 1970 to 2016, deaths from colon cancer plummeted 53 percent, the researchers reported.

Siegel noted that "lung cancer still kills more Americans than breast, prostate and colon cancer combined."

Deaths from some cancers, however, rose. For example, deaths from liver cancer increased each year among men and women. Pancreatic cancer deaths rose slightly among men. Brain cancer deaths also rose each year. Other cancer deaths on the rise are soft-tissue cancers (such as heart) and oral cancers linked to the human papillomavirus (HPV).

Although a vaccine for HPV is available, Paskett said, too few girls and boys are being vaccinated. The vaccine can prevent 70 percent of cervical cancers as well as many oral cancers and genital warts.

Cancer is the second leading cause of death after heart disease, the researchers reported. But cancer is the leading cause of death in many states and among Hispanics, Asian Americans and people under 80 years of age.

For cancers such as leukemia, non-Hodgkin lymphoma, pancreatic and ovarian cancers, death rates vary only slightly between the rich and poor, the investigators found.

The study authors also said that cases of melanoma have been increasing, as well as cases of liver, thyroid, uterine and pancreatic cancer.

Paskett pointed out that "we have made great strides. But we have a long way to go."

SOURCES: Rebecca Siegel, M.P.H., scientific director, surveillance research, American Cancer Society; Electra Paskett, Ph.D., co-program leader, cancer control program, Ohio State University Comprehensive Cancer Center, Columbus; Jan. 8, 2019, CA: A Cancer Journal for Clinicians, online
Copyright © 2019 All rights reserved.

• "I have AML and it’s relapsed twice because of FLT 3 mutation. Anyone else experienced this?"
   
• "This is my 3rd cancer bout as well. I understand all about the fatigue. I wish you and your family the very best."
   
• "I am an Acute Myeloid Leukemia survivor of a year and a half. I myself had to go though a stem cell transplant my sister was my match."

What was your reaction to the types of cancer treatments available to you after your diagnosis? Share in the comments below!